H.C. Wainwright Thinks Clearside Biomedical’s Stock is Going to Recover
July 27 2022 - 06:17AM
TipRanks
H.C. Wainwright analyst Yi Chen reiterated a Buy rating on
Clearside Biomedical (CLSD – Research Report) today and set a price
target of $10.00. The company's shares closed last Tuesday at
$1.62, close to its 52-week low of $1.26. According to
TipRanks.com, Chen is currently ranked with 0 stars on a 0-5 stars
ranking scale, with an average return of -13.6% and a 31.9% success
rate. Chen covers the Healthcare sector, focusing on stocks such as
Interpace Diagnostics Group, HTG Molecular Diagnostics, and
EyePoint Pharmaceuticals. The word on The Street in general,
suggests a Strong Buy analyst consensus rating for Clearside
Biomedical with a $9.67 average price target, a 523.
https://www.tipranks.com/news/blurbs/h-c-wainwright-thinks-clearside-biomedicals-stock-is-going-to-recover-2?utm_source=advfn.com&utm_medium=referral
Clearside Biomedical (NASDAQ:CLSD)
Historical Stock Chart
From Jan 2023 to Feb 2023
Clearside Biomedical (NASDAQ:CLSD)
Historical Stock Chart
From Feb 2022 to Feb 2023